NEW YORK – Create Medicines has started clinically testing an in vivo CAR therapy that comprises a cancer-killing medley of T, NK, and myeloid cells.
The European Commission will now consider the committee's positive opinions as it determines whether to grant marketing authorization to the drugs.
The firm said the CHMP would not support the application due to concerns about the control arm used in the Phase III PSMAfore trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results